双歧杆菌三联活菌胶囊治疗溃疡性结肠炎的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 双歧杆菌三联活菌胶囊治疗溃疡性结肠炎的临床观察
TITLE:
摘要: 目的:观察双歧杆菌三联活菌胶囊治疗溃疡性结肠炎(UC)的疗效和安全性。方法:94例UC患者随机均分为对照组和研究组。对照组患者给予营养支持、清淡饮食、5-氨基水杨酸等常规治疗;研究组患者在对照组治疗的基础上加服双歧杆菌三联活菌胶囊420 mg,每日3次。两组患者疗程均为8周。观察两组患者的临床疗效,治疗前后血清D-乳酸、二胺氧化酶(DAO)水平及不良反应发生情况。结果:研究组患者总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者血清D-乳酸、DAO水平均显著低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.05或P<0.01)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在常规治疗的基础上,双歧杆菌三联活菌胶囊治疗UC的疗效和安全性均较好。
ABSTRACT: OBJECTIVE: To observe the efficacy and safety of Bifid triple viable capsule in the treatment of ulcerative colitis (UC). METHODS: 94 patients with UC were randomly divided into control group and research group. Control groups was given nutrition support, light diet and 5-amino salicylic acid and other conventional treatment; research group was additionally given 420 mg Bifid triple viable capsule, 3 times aday. Treatment course for both group was 8 weeks. The clinical efficacy, and serum D-lactic acid, diamine oxidase (DAO) levels before and after treatment, and incidence of adverse reactions in 2 groups were observed. RESULTS:The total effective rate in research group was significantly higher than control group, the difference was statistically significant(P<0.05); after treatment, serum D-lactic acid, DAO levels in 2 groups were significantly lower than before, and research group was lower than control group, the differences were statistically significant(P<0.05 or P<0.01); and there was no significant difference in the incidence of adverse reactions(P>0.05). CONCLUSIONS: Based on the conventional treatment, both the efficacy and safety of Bifid triple viable capsule are good in the treatment of UC.
期刊: 2015年第26卷第36期
作者: 毛立新,郭元春,钱剑
AUTHORS: MAO Li-xin,GUO Yuan-chun,QIAN Jian
关键字: 溃疡性结肠炎;双歧杆菌三联活菌胶囊;肠黏膜屏障;疗效;安全性
KEYWORDS: Ulcerative colitis; Bifid triple viable capsule; Intestinal mucous membrane barrier; Efficacy; Safety
阅读数: 358 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!